Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.

Author: FaissnerSimon, GoldRalf

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review discusses the latest developments in multiple sclerosis treatment, including the emergence of second-generation therapeutics with reduced side effects and more tailored approaches. It highlights the introduction of diroximel fumarate, a second-generation fumarate with reduced gastrointestinal side effects, and novel, selective sphingosine-1-phosphate receptor modulators like siponimod, ozanimod, and ponesimod, all of which are oral formulations. The review also discusses the advancements in B-cell-targeted therapies, including ocrelizumab, ofatumumab, and ublituximab, as well as upcoming therapies targeting Bruton's tyrosine kinase. These developments offer a more individualized treatment approach for multiple sclerosis, addressing patient needs with significant impacts on relapses, disability progression, and quality of life.
Paper Details　
Original Abstract of the Article :
Multiple sclerosis treatment made substantial headway during the last two decades with the implementation of therapeutics with new modes of action and routes of application. We are now in the situation that second-generation molecules, approved since 2018, are on the market, characterized by reduced...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307218/

データ提供：米国国立医学図書館（NLM）

Navigating the Sands of Multiple Sclerosis: A Journey Through Novel Therapies

The sands of time have shifted, revealing new and innovative treatments for multiple sclerosis (MS). This research presents a comprehensive overview of the ever-evolving landscape of MS therapies, highlighting the emergence of second-generation molecules with improved efficacy and reduced side effects.

The researchers guide us through the advancements in MS treatment, from the introduction of second-generation fumarates like diroximel fumarate with its reduced gastrointestinal side effects to the development of oral sphingosine-1-phosphate receptor modulators with fewer off-target effects. They also shed light on the growing role of B-cell-targeted therapies, such as ocrelizumab and ofatumumab. This research serves as a compass, guiding us through the complex terrain of MS treatment options.

A New Dawn for MS Treatment: Tailored Therapies for a Personalized Journey

The emergence of these novel therapies marks a significant shift in the treatment paradigm for MS. These advancements are paving the way for more personalized and effective care. The research emphasizes the importance of individualizing treatment plans, taking into account each patient's unique needs and disease characteristics. This approach is akin to a traveler choosing the best path across the desert, considering their specific resources and limitations.

A Glimpse into the Future: Hope on the Horizon

This research not only showcases the impressive progress in MS treatment but also offers a glimpse into the future. The ongoing development of oral Bruton's tyrosine kinase inhibitors holds immense promise for improving the lives of individuals living with MS. The researchers highlight the potential of these inhibitors to further optimize treatment strategies and provide a more comprehensive approach to managing the disease.

Dr.Camel's Conclusion

The research on new MS therapies is a beacon of hope in the desert of this challenging disease. It showcases the remarkable advancements in our understanding of MS and the development of targeted therapies. The journey continues, and the future holds the promise of even more effective and personalized treatments for individuals living with MS.

Date :
  1. Date Completed 2022-08-04
  2. Date Revised 2022-11-04
Further Info :

Pubmed ID

35869335

DOI: Digital Object Identifier

PMC9307218

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.